These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 19912682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [Abstract] [Full Text] [Related]

  • 7. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, Mao Q.
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [Abstract] [Full Text] [Related]

  • 17. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB, Atabay A, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.